[صفحه اصلی ]   [Archive]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
بخش‌های اصلی
صفحه اصلی::
اطلاعات نشریه::
برای نویسندگان::
آرشیو مجله و مقالات::
برای داوران::
ثبت نام و اشتراک::
تماس با ما::
تسهیلات پایگاه::
بایگانی مقالات زیر چاپ::
::
جستجو در پایگاه

جستجوی پیشرفته
..
دریافت اطلاعات پایگاه
نشانی پست الکترونیک خود را برای دریافت اطلاعات و اخبار پایگاه، در کادر زیر وارد کنید.
..
:: دوره 11، شماره 1 - ( 10-1398 ) ::
جلد 11 شماره 1 صفحات 46-41 برگشت به فهرست نسخه ها
Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
چکیده:   (3604 مشاهده)
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting. This study aimed to evaluate the efficacy and safety of generic sofosbuvir/ledipasvir (SOF/LDV) in a real-life clinical experience.
Methods: In this prospective cohort study, patients with chronic HCV infection who referred to Middle East Liver Diseases (MELD) Center were included. Based on the patients’ condition, they were treated with SOF/LDV fixed-dose combination with or without ribavirin (RBV) for 12 or 24 weeks.
Results: A total of 30 (M/F: 19/11) patients with chronic HCV genotype 1 infection with a mean age of 49.8 years were treated with generic SOF/LDV with (9 patients) or without (11 patients) RBV for 12 (27 patients) or 24 (3 patients) weeks. Ten (33.3%) had cirrhosis and 13 (43.3%) with a previous history of treatment with interferon (IFN)-based regimens. Among the 30 patients, 26 (86.7%, 95% CI=70.3%-94.7%) achieved a rapid virologic response, 30 (100%, 95% CI=88.7%-100%) achieved the end of treatment response and 30 (100%, 95% CI=88.7%-100%) achieved a sustained virologic response. No severe treatment adverse event was observed however, 6 (20%) patients experienced mild to moderate adverse events.
Conclusion: The treatment of HCV genotype 1 infection with generic SOF/LDV found to be safe and effective even in patients with cirrhosis and previous history of treatment with IFN-based treatments.
متن کامل [PDF 343 kb]   (1350 دریافت)    
نوع مطالعه: Original Article | موضوع مقاله: Infectious Diseases
دریافت: 1397/5/9 | پذیرش: 1398/6/6 | انتشار: 1398/9/24
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

CAPTCHA



XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharafi H, Alavian S H, Behnava B, Rezaee-Zavareh M S, Nikbin M, Alavian S M. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian J Intern Med 2020; 11 (1) :41-46
URL: http://caspjim.com/article-1-1576-fa.html

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. 1. 1398; 11 (1) :41-46

URL: http://caspjim.com/article-1-1576-fa.html



بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.
دوره 11، شماره 1 - ( 10-1398 ) برگشت به فهرست نسخه ها
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4645